Inclusion Criteria:

• * Breast cancer diagnosis stage I-III
• * Within 18-months of treatment completion (defined as completion of all oncologic treatments expect oral maintenance therapy)
• * Age 18 years or older
• * At increased risk for cardiovascular disease based on one of the following; a.Treatment with either anthracycline-based or anti-HER2 therapy-based treatment regimen plus the presence of: \>2 cardiovascular heart disease risk factors (smoking, hypertension, diabetes mellitus, obesity, dyslipidemia), OR Age (\>60 years) at cancer treatment, OR Left ventricular ejection fraction \<50%as determined with a clinically ordered echo scan within 6 months of enrollment, b.Treatment with anthracycline followed by trastuzumab
• * Ability to understand and the willingness to sign a written informed consent.

Exclusion Criteria:

• * Planned surgery during the study period.
• * Under cardiology care for known high-risk cardiovascular disease defined as the presence of any of the following: severe, unrevascularized coronary artery disease, severe valvular heart disease, advanced heart failure with a left ventricular ejection fraction \<35%)
• * Metastatic cancer
• * Unable to exercise (e.g., inability to complete a modified stress test or musculoskeletal condition that prevents adequate participation in exercise)
• * Adults unable to give consent, pregnant or lactating women, and prisoners are excluded from this study.